Literature DB >> 16250883

Alternative approach to blood screening using the ExaVir reverse transcriptase activity assay.

Elizabeth Seyoum1, Dawit Wolday, Teferi Mekonen, Mulu Girma, Tsehaynesh Meselle, Clas Källander, Simon Gronowitz, Sven Britton.   

Abstract

408 non-selected samples were obtained from healthy, adult individuals donating blood at the Ethiopian Red Cross Society-National Blood Transfusion Service. All samples were screened for HIV using the Vironostika Ag/Ab test, the Amplicor DNA PCR and examined for the presence of HIV reverse transcriptase (RT) using the ExaVir Load test (version 2). A panel of supplementary tests was used to evaluate the HIV status of the discordant samples and to confirm positivity. One aim was to assess an RT based test for screening for HIV in comparison with other more conventional tests. An HIV-prevalence of 3.4 % (14/408) was found. The Vironostika Ag/Ab test produced 391 negative, and according to the supplementary testing, 14 true- and three false- positive test results. The corresponding figures for the Amplicor DNA PCR test was 384 negative, 14 true- and two extra probably false -positive samples. In addition, the DNA PCR generated eight indeterminate results. The colorimetric version of the ExaVir load test exhibited 100 % specificity and detected RT in 13 of the true positive samples, but failed to detect one sample containing 200 HIV RNA copies /mL. This sample was detectable in the fluorimetric version of the test. The detection of RT activity in addition to the currently used markers would seem to have a potential for use in blood screening.

Mesh:

Substances:

Year:  2005        PMID: 16250883     DOI: 10.2174/157016205774370438

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  4 in total

1.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

2.  Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients.

Authors:  Pedro Borrego; Maria Fátima Gonçalves; Perpétua Gomes; Lavínia Araújo; Inês Moranguinho; Inês Brito Figueiredo; Isabel Barahona; José Rocha; Claudino Mendonça; Maria Cesarina Cruz; Jorge Barreto; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

3.  Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.

Authors:  Ming Chang; Geoffrey S Gottlieb; Joan A Dragavon; Stephen L Cherne; Donna L Kenney; Stephen E Hawes; Robert A Smith; Nancy B Kiviat; Papa Salif Sow; Robert W Coombs
Journal:  J Clin Virol       Date:  2012-07-24       Impact factor: 3.168

4.  Sero-epidemiology and associated factors of HIV, HBV, HCV and syphilis among blood donors in Ethiopia: a systematic review and meta-analysis.

Authors:  Mulugeta Melku; Sintayehu Ambachew; Bamlaku Enawgaw; Molla Abebe; Zegeye Abebe; Tekalign Deressa; Debasu Damtie; Belete Biadgo; Belay Tessema; Demeke Geremew; Asemarie Kebede; Berhanu Woldu; Takele Teklu; Elias Shiferaw
Journal:  BMC Infect Dis       Date:  2021-08-09       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.